Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckRobert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|New England Journal of Medicine|2016Cited by 5.1k
Nivolumab vs investigator’s choice in recurrent or metastatic squamous cell carcinoma of the head and neck: 2-year long-term survival update of CheckMate 141 with analyses by tumor PD-L1 expressionRobert L. Ferris, Maura L. Gillison, George R. Blumenschein et al.|Oral Oncology|2018Cited by 802
Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trialKevin J. Harrington, J. Guigay, Robert L. Ferris et al.|The Lancet Oncology|2017Cited by 431
Durvalumab with or without tremelimumab in patients with recurrent or metastatic head and neck squamous cell carcinoma: EAGLE, a randomized, open-label phase III studyRobert L. Ferris, Lisa Licitra, Robert I. Haddad et al.|Annals of Oncology|2020Cited by 365
Durvalumab for recurrent or metastatic head and neck squamous cell carcinoma: Results from a single-arm, phase II study in patients with ≥25% tumour cell PD-L1 expression who have progressed on platinum-based chemotherapyDan P. Zandberg, Ricard Mesı́a, Alain P. Algazi et al.|European Journal of Cancer|2018Cited by 267